Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 4507-4520

  Lozano Pérez, Antonio Abel ^a   Rodriguez Nogales, Alba ^b   Ortiz Cullera, Víctor ^a   Algieri, Francesca ^b   Garrido Mesa, José ^b   Zorrilla, Pedro ^b   Rodriguez Cabezas, M Elena ^b   Garrido Mesa, Natividad ^b   Pilar Utrilla, M ^b   de Matteis, Laura ^c   de la Fuente, Jesús Martínez ^c   Cenis, José Luis ^a   Gálvez, Julio ^b  

^a INSTITUTO MURCIANO DE INVESTIGACIÓN Y DESARROLLO AGRARIO Y ALIMENTARIO IMIDA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Antioxidant; Cytokines; Immunomodulatory; RAW 264.7 macrophage cells; TNBS rat colitis

Indexed keywords

DEXAMETHASONE; LIPOPOLYSACCHARIDE; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; RESVERATROL; SILK FIBROIN NANOPARTICLE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CYTOKINE; DELAYED RELEASE FORMULATION; SILK; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG ADSORPTION; DRUG MECHANISM; DRUG SOLUBILITY; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE FUNCTION; MACROPHAGE; MOUSE; NONHUMAN; RAT; ANALYSIS OF VARIANCE; ANIMAL; CELL LINE; CHEMISTRY; COLON; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; INFLAMMATORY BOWEL DISEASES; METABOLISM; PARTICLE SIZE; PHARMACOKINETICS; PHARMACOLOGY; THERAPEUTIC USE;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; COLON; CYTOKINES; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; INFLAMMATORY BOWEL DISEASES; NANOPARTICLES; PARTICLE SIZE; RATS; SILK; STILBENES;

EID: 84925370900     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S68526     Document Type: Article

References (41)

1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390-407.
2. Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther. 2011;33(1):23-32.
3. Collnot EM, Ali H, Lehr CM. Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161(2):235-246.
4. Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. Soluplus-solubilized citrated camptothecin-a potential drug delivery strategy in colon cancer. AAPS PharmSciTech. 2012;13(1):59-66.
5. Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres. Int J Nanomedicine. 2011;6:1057-1068.
6. Thakral NK, Ray AR, Jacobsen J, Bar-Shalom D, Eriksson AH, Majumdar DK. Colon targeting of fluticasone propionate inclusion complex: a novel approach in inflammatory bowel disease. J Incl Phenom Macrocycl Chem. 2013;75:175-184.
7. Vepari C, Kaplan DL. Silk as a Biomaterial. Prog Polym Sci. 2007; 32(8-9):991-1007.
8. Mathur AB, Gupta V. Silk fibroin-derived nanoparticles for biomedical applications. Nanomedicine (Lond). 2010;5(5):807-820.
9. Wenk E, Wandrey AJ, Merkle HP, Meinel L. Silk fibroin spheres as a platform for controlled drug delivery. J Control Release. 2008;132(1): 26-34.
10. Zhang YQ, Shen WD, Xiang RL, Zhuge LJ, Gao WJ, Wang WB. Formation of silk fibroin nanoparticles in water-miscible organic solvent and their characterization. J Nanopart Res. 2007;9(5):885-900.
11. Yamada H, Igarashi Y, Takasu Y, Saito H, Tsubouchi K. Identification of fibroin-derived peptides enhancing the proliferation of cultured human skin fibroblasts. Biomaterials. 2004;25(3):467-472.
12. Chen M, Shao Z, Chen X. Paclitaxel-loaded silk fibroin nanospheres. J Biomed Mater Res A. 2012;100(1):203-210.
13. Gupta V, Aseh A, Ríos CN, Aggarwal BB, Mathur AB. Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy. Int J Nanomedicine. 2009;4:115-122.
14. Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int J Pharm. 2007;341(1-2):221-229.
15. Kim ED, Bayaraa T, Shin EJ, Hyun CK. Fibroin-derived peptides stimulate glucose transport in normal and insulin-resistant 3T3-L1 adipocytes. Biol Pharm Bull. 2009;32(3):427-433.
16. Kim DW, Hwang HS, Kim DS, et al. Enhancement of anti-inflammatory activity of PEP-1-FK506 binding protein by silk fibroin peptide. J Microbiol Biotechnol. 2012;22(4):494-500.
17. Kimura T, Yamada H, Tsubouchi K, Doi K. Accelerating effects of silk fibroin on wound healing in hairless descendants of Mexican hairless dogs. J Appl Sci Res. 2007;3:1306-1314.
18. Martínez-Mora C, Mrowiec A, García-Vizcaíno EM, Alcaraz A, Cenis JL, Nicolás FJ. Fibroin and sericin from Bombyx mori silk stimulate cell migration through upregulation and phosphorylation of c-Jun. PLoS One. 2012;7(7):e42271.
19. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109(4): 1344-1367.
20. Marques FZ, Markus MA, Morris BJ. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol. 2009;41(11):2125-2128.
21. Martín AR, Villegas I, Sánchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol. 2006;147(8):873-885.
22. Ajisawa A. Dissolution of silk fibroin with calcium chloride/ethanol aqueous solution. J Seric Sci Jpn. 1998;67(2):91-94.
23. Granger DL, Taintor RR, Boockvar KS, Hibbs JB. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1996;268:142-151.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
25. Camuesco D, Peran L, Comalada M, et al. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm Bowel Dis. 2005;11(3):265-271.
26. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87(6):1344-1350.
27. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 1985;113:548-555.
28. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nature Protocols. 2008;3:1101-1108.
29. Shao J, Li X, Lu X, et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces. 2009;72(1):40-47.
30. Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. 2008; 25(11):2593-2600.
31. Sanna V, Roggio AM, Siliani S, et al. Development of novel cationic chitosan-and anionic alginate-coated poly(D,L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int J Nanomedicine. 2012;7:5501-5516.
32. Wadsworth TL, Koop DR. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem Pharmacol. 1999;57(8):941-949.
33. Nunes T, Barreiro-de Acosta M, Marin-Jiménez I, Nos P, Sans M. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis. 2013;7(3):183-191.
34. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1995;272(1):417-422.
35. Algieri F, Zorrilla P, Rodriguez-Nogales A, et al. Intestinal anti-inflammatory activity of hydroalcoholic extracts of Phlomis purpurea L. and Phlomis lychnitis L. in the trinitrobenzenesulphonic acid model of rat colitis. J Ethnopharmacol. 2013;146(3):750-759.
36. León AJ, Gómez E, Garrote JA, et al. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm. 2009;2009:580450.
37. García-Ramallo E, Marques T, Prats N, Beleta J, Kunkel SL, Godessart N. Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J Immunol. 2002; 169(11):6467-6473.
38. Tytgat KM, van der Wal JW, Einerhand AW, Büller HA, Dekker J. Quantitative analysis of MUC2 synthesis in ulcerative colitis. Biochem Biophys Res Commun. 1996;224(2):397-405.
39. Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology. 2009;137(1):209-220.
40. Wang Y, Srinivasan K, Siddiqui MR, George SP, Tomar A, Khurana S. A novel role for villin in intestinal epithelial cell survival and homeostasis. J Biol Chem. 2008;283(14):9454-9464.
41. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619-1635.